Response of Transplanted AKR Leukemia to Combination Therapy With Amphotericin Band 1,3-Bis(2-chloroethyl)-1-nitrosourea: Dose and Schedule Dependency2
- 1 April 1977
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 58 (4) , 949-953
- https://doi.org/10.1093/jnci/58.4.949
Abstract
A number of different amphotericin B (AmB)-1,3-bis(2-chloroethyl)-1-nitrosourea (BCN U) treatment regimens were evaluated with our model of transplantable AKR leukemia. We found that dose levels and treatment schedules were critical in determining the number of survivors. A 4-day treatment regimen of 0.5 mg AmB/mouse on days 1, 2, 3, and 4 and 0.2 mg BCNU/mouse on day 4 was found to be the most effective and has been chosen as our standard regimen. The efficacy of the treatment regimen depended on the presence of a large tumor burden, and the response was abolished when the mice were preirradiated or treated with the immunosuppressive agent, cyclophosphamide. These results, as well as others which we discuss, supported our notion that AmB affected host immune response to the tumor.Keywords
This publication has 0 references indexed in Scilit: